HEART TEST LABORATORIES INC (HSCS)       1.26  -0.14 (-10%)

1.26  -0.14 (-10%)

US42254E1047 - Common Stock


Fundamental Rating

2

Overall HSCS gets a fundamental rating of 2 out of 10. We evaluated HSCS against 221 industry peers in the Health Care Equipment & Supplies industry. HSCS has a bad profitability rating. Also its financial health evaluation is rather negative. HSCS is quite expensive at the moment. It does show a decent growth rate.




Profitability

Profitability Rating

0

The profitability ratios for HSCS are negative, so there is not much use analyzing them.
HSCS's Return On Assets of -86.73% is worse than the rest of the industry. The industry average Return On Assets is -19.67%. 84% of the industry peers have a better Return On Assets.

HSCS has a very weak Piotroski-F score of 1.00. This is an indication of health and profitability issues for HSCS.
VS Industry

ROA (-86.73%) VS Industry: 16% outperformed.

-771.54
117.69

Valuation

Valuation Rating

1

When comparing the current price to the book value of HSCS, we can conclude it is valued correctly. It is trading at 3.57 times its book value.
Compared to an average industry price book ratio of 2.62, HSCS is valued in line with its industry peers.

HSCS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HSCS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Price/Book (3.57) VS Industry: 43% outperformed.

1,098.53
0.06

Growth

Growth Rating

5

HSCS is expected to show quite a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 11.57% yearly.
Based on estimates for the next 5 years, HSCS will show a very strong growth in Revenue. The Revenue will grow by 1431.55% on average per year.

The earnings per share for HSCS have decreased strongly by -92.26% in the last year.
The Revenue for HSCS has decreased by -43.87% in the past year. This is quite bad

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -92.26% -93.14% -85.61% -83.48% 11.57%
RevenueN/A N/A -43.87% -78.71% 419.35% 719.41% 1431.55%

Health

Health Rating

2

HSCS has a Current Ratio of 3.53. This indicates that HSCS is financially healthy and has no problem in meeting its short term obligations.
HSCS has a Quick Ratio of 3.09. This indicates that HSCS is financially healthy and has no problem in meeting its short term obligations.
HSCS has a Current Ratio comparable to the industry average, which is at 3.69.
The Quick Ratio is in line with the industry averages, which is at 2.91.

Compared to an average industry Debt to Equity Ratio of 0.09, HSCS is more dependent on financing than its industry peers.
HSCS has an Altman-Z score of -13.72. This is a bad value and indicates that HSCS is not financially healthy and even has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 1.87, HSCS is in worse financial state than most of its industry peers. 92% of its industry peers have a better Altman-Z score.
HSCS has a very weak Piotroski-F score of 1.00. This is an indication of health and profitability issues for HSCS.
VS Industry

Debt/Equity (0.35) VS Industry: 32% outperformed.

336.87
0.00

Quick Ratio (3.09) VS Industry: 53% outperformed.

0.06
31.22

Current Ratio (3.53) VS Industry: 47% outperformed.

0.13
31.22

Altman-Z (-13.72) VS Industry: 8% outperformed.

-105.06
71.69

Dividend

Dividend Rating

0

No dividends for HSCS!.

HSCS Daily chart

HEART TEST LABORATORIES INC1.26

NASDAQ:HSCS (12/8/2022, 7:00:02 PM)-0.14 (-10%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Health Care Equipment & Services
GICS Industry Health Care Equipment & Supplies
Earnings (Last) 09-23 2022-09-23/bmo Earnings (Next) 12-13 2022-12-13/bmo
Ins Owners 10.91% Inst Owners N/A
Market Cap 10.30M Analysts 82.5
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 716.75 P/B 3.57
EV/EBITDA N/A
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -92.26% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -208.44%
EPS Next Y -93.14% EPS Next 2Y -85.61%
EPS Next 3Y -83.48% EPS Next 5Y 11.57%
Revenue growth 1Y -43.87% Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q -57.22%
Revenue Next Year -78.71% Revenue Next 2Y 419.35%
Revenue Next 3Y 719.41% Revenue Next 5Y 1431.55%
Health
Current Ratio 3.53 Quick Ratio 3.09
Altman-Z -13.72 F-Score 1
Debt/Equity 0.35 WACC 9.36%
ROIC/WACC N/A
Profitability
ROA -86.73% ROE N/A
ROICexgc N/A ROIC N/A
PM N/A OM N/A
Asset Turnover 0

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA